What is the recommended treatment for restless legs syndrome in a patient with Parkinson disease?

Treatment of Restless Legs Syndrome in Parkinson's Disease

In patients with Parkinson's disease who develop restless legs syndrome, prioritize gabapentin, pregabalin, or gabapentin enacarbil as first-line therapy, while avoiding or minimizing dopamine agonists due to the risk of augmentation—a critical consideration given that these patients are already on dopaminergic therapy for their PD.

First-Line Treatment Approach

The 2025 American Academy of Sleep Medicine guidelines provide strong recommendations for alpha-2-delta ligands in RLS treatment 1:

• Gabapentin enacarbil (strong recommendation, moderate certainty)
• Gabapentin (strong recommendation, moderate certainty)
• Pregabalin (strong recommendation, moderate certainty)

These agents are particularly advantageous in PD patients because they avoid compounding dopaminergic stimulation and carry no augmentation risk—a phenomenon where RLS symptoms paradoxically worsen with chronic dopamine agonist use.

Critical Consideration: Dopamine Agonists Should Be Avoided

The AASM now suggests against the standard use of dopamine agonists including pramipexole, ropinirole, rotigotine, and levodopa for RLS 1. While these agents may provide short-term symptom relief, they carry significant long-term risks, particularly augmentation. The guidelines note these may only be considered "in patients who place a higher value on the reduction of restless legs symptoms with short-term use and a lower value on adverse effects with long-term use (particularly augmentation)" 1.

This represents a paradigm shift from older practices. In PD patients specifically, this is especially important because:

• They are already receiving dopaminergic therapy for motor symptoms
• Nighttime levodopa use is associated with higher RLS risk (OR=2.049) 2
• Dopaminergic over-excitation at night may contribute to RLS pathogenesis 2

Iron Repletion Strategy

Check iron parameters and treat if deficient:

• IV ferric carboxymaltose is strongly recommended when iron parameters are appropriate (strong recommendation, moderate certainty) 1
• Consider IV low molecular weight iron dextran or ferumoxytol as alternatives (conditional recommendations) 1
• Oral ferrous sulfate can be used (conditional recommendation, moderate certainty) 1

Important caveat: One review suggests iron deficiency "should probably not be compensated" specifically in PD patients with RLS 3, though this contradicts the general AASM guidelines. Given the strong AASM recommendation and the safety profile of iron repletion, checking and correcting iron deficiency remains prudent.

Second-Line and Adjunctive Options

If alpha-2-delta ligands are insufficient:

• Opioids (extended-release oxycodone and others): conditional recommendation, moderate certainty 1
• Dipyridamole: conditional recommendation, low certainty 1

Special Consideration: Deep Brain Stimulation

For PD patients already undergoing or being considered for subthalamic nucleus (STN) DBS:

• STN-DBS can improve RLS symptoms in 43-100% of PD patients 4, 5
• Mean RLS score reductions of 84% have been reported 5
• The effect appears direct rather than medication-related 4
• However, rare cases of DBS-induced RLS have been reported 6

Practical Algorithm

1. Assess iron status (ferritin, transferrin saturation) and replicate if deficient
2. Review current PD medications: Consider timing of levodopa doses, particularly avoiding late-night dosing
3. Initiate alpha-2-delta ligand: Start with gabapentin enacarbil, gabapentin, or pregabalin
4. If inadequate response: Add low-dose opioid therapy
5. Avoid adding or increasing dopamine agonists unless short-term benefit outweighs long-term augmentation risk
6. For patients with STN-DBS: Monitor for RLS improvement post-operatively

Common Pitfalls to Avoid

• Do not reflexively increase dopaminergic therapy for RLS in PD patients—this may worsen symptoms long-term through augmentation
• Do not use cabergoline (strong recommendation against) 1
• Avoid benzodiazepines (clonazepam), carbamazepine, valproic acid, and bupropion—all have recommendations against use 1
• Do not dismiss RLS as simply PD motor symptoms—proper diagnosis using validated criteria (IRLS) is essential 7

Impact on Quality of Life

RLS significantly worsens sleep quality (higher PDSS-2 scores), increases nocturnal pain, and reduces overall quality of life in PD patients 7, 2. Greater RLS symptom severity directly predicts worse QoL scores 2, making aggressive treatment essential for maintaining patient function and well-being.